chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm injection site was tingling; numbing to her fingertips; bruise to the top of her hand; headache; nauseous; pain at the injection site; feeling yucky; tiredness; This is a spontaneous report from a contactable consumer or other non-healthcare professional. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number and Expiration date were not reported), via an unspecified route of administration in arm on 24Feb2021 as a dose 1, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The consumer stated that, she had her first dose of the Pfizer-BioNTech COVID-19 vaccine yesterday. The caller stated that, she left and it takes 20 minutes for her to get home and back to work and then her arm injection site was tingling with numbing to her fingertips. The caller stated that, she got to work and it was so busy she jumped in working, then a little while later saw she had a bruise to the top of her hand where the wrist meets the top of where her hand starts, about the size of a fifty cent piece. Stated that, she knows she didn't hit it, she would have felt the tingling if she had. Stated that, her bruise was starting to go away. Stated that, she called her pharmacy and they suggested for her to go to the urgent care, which she did. Stated that, the urgent care said they hadn't heard about bruise like this. Stated that, she also has a headache, was nauseous, has pain at the injection site, was feeling yucky and has tiredness. The caller stated that, the provider at the urgent care suggested and stated that, she had the injection and chose to take the next day off work and that she had same symptoms though she didn't have a bruise. No further details provided about provider that had side effects. The outcome of the events for bruise to the top of her hand was recovering while for the other events was unknown.  No follow-up attempts are needed. No further information is expected.
DIFFICULTY IN MOVING RIGHT ARM; NUMBNESS IN ARM; This spontaneous report received from a parent concerned a 22 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On APR-2021, the subject experienced difficulty in moving right arm. On APR-2021, the subject experienced numbness in arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the difficulty in moving right arm and numbness in arm was not reported. This report was non-serious.; Sender's Comments: V0 Medical Assessment comment not required as per standard procedure as the case assessed as non-serious.
Neck pain one week after Vx.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 46 year-old male patient received bnt162b2 (BNT162B2), administration date 19Mar2021 (Lot number: EN6207) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NECK PAIN (non-serious) with onset Mar2021, outcome "unknown", described as "Neck pain one week after Vx.". It was unknown if therapeutic measures were taken as a result of neck pain.  Additional information: It was unknown is patient was diagnosed with COVID-19 prior to vaccination. It was also unknown if patient has been tested for COVID-19 since the vaccination.  No follow-up attempts are possible. No further information is expected.
Patient received expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 5-year-old male patient who received DTPa-IPV (Kinrix) (batch number H9Y52, expiry date 31st January 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 14th February 2022, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 14th February 2022, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The case was reported by the Medical assitant. The reporter stated that, the patient received an expired dose of Kirinx, which led to expired vaccine used. The reporter consented to follow up.
pt had sz like episode on 23SEP92 & another 24SEP92; no fever or other signs of illness was taken to hosp ER; p/2nd sz no abnormal findings there;
Patient states he had pain at the injection site initially but no further issues immediately after vaccination. He states that approximately 7-10 days after vaccination he developed significant pain of L arm and weakness in radial nerve distribution. He was diagnosed with radial nerve neuropathy and began on treatment with Neurontin and NSAIDs. Symptoms have improved significantly but not yet fully resolved.
Irregular menstruation and menorrhagia following COVID-19 vaccine on 4/28/2021.  Had irregular breakthrough bleeding on 5/7 that lasted 3 days and then again on 5/20 - 5/27 that lasted greater than 7 days with very heavy clots which is irregular for patient.  Patient  convinced that it is due to COVID-19 vaccine. She reports compliance with daily OCP.
Itchiness in the injection site; Broke out (like a rash) in the injection site; Arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm soreness), VACCINATION SITE PRURITUS (Itchiness in the injection site) and VACCINATION SITE RASH (Broke out (like a rash) in the injection site) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No medical history provided by the reporter.  Concomitant products included GABAPENTIN for Arthritis, OXYBUTYNIN for Bladder incontinence, DULOXETINE for Gastroesophageal reflux, PANTOPRAZOLE for an unknown indication.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced PAIN IN EXTREMITY (Arm soreness). On 13-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PRURITUS (Itchiness in the injection site) and VACCINATION SITE RASH (Broke out (like a rash) in the injection site). At the time of the report, PAIN IN EXTREMITY (Arm soreness), VACCINATION SITE PRURITUS (Itchiness in the injection site) and VACCINATION SITE RASH (Broke out (like a rash) in the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment include Put gold bond cream    Reporter did not allow further contact
Patient became light headed and diaphoretic shortly after administration of vaccine and was helped to a seated position on the floor. No lose of consciousness. After a few minutes he was able to eat snacks and was monitored for 30 minutes. Was discharged after 30 minutes with a friend for monitoring. He had no residual effects. Patient states that this had happened to him multiple times and anticipated it coming.
mom stated that he ran a fever of 102 and the local site was red and swollen and she went to see her pedirician the next day and it stated it was ok and if it got worse to take him to the emergency room but it resolved
9/17/09- Rec'd Tdap, varicella at Health Dept. 9/18/09- c/o arm, hand spasms, mild difficulty breathing, general malaise. Injection site; no redness, swelling or pain.
This spontaneous report was received from a female healthcare worker of an unknown age, reporting on herself, via a company representative. Medical history and concurrent conditions were not reported. In July 2012 (reported as two years ago at the end of July or beginning of August 2012), the patient was vaccinated with a dose ZOSTAVAX (dose, dose number, lot number, expiration date and route were not reported). Co-suspect and concomitant therapies were not reported. The healthcare worker reported that on 25-JAN-2015, she experienced headache on the left side of her head that was so bad she almost went to the emergency room. On 29-JAN-2015 (also reported as recently), she saw a little red mark under her bangs. The healthcare worker developed shingles the left side of her head and face: head, forehead, a "few" on her eyelid, and a "few" on her hairline. The healthcare worker described the shingles as "they never oozed or seeped at all, got little bumps and stuff, never blistered and popped, absorbed back into my body and turned really, really red and really, really sore in my head". The healthcare worker reported she has to wash her hair in the sink and with baby shampoo because she "can't stand" the shower on the shingles she also "can't stand" the blow dryer or the curling iron since an unknown date. On 28-JAN-2015, healthcare worker reported that the headache as recovered. At the time of the report the outcome for shingles was not recovered. The healthcare worker stated she seek medical attention on an unspecified healthcare professional and was prescribed with VALTREX for the shingles, on an unknown date. Additional information has been requested.
Woke up with swelling to injection site, weak and feverish,  aching bones and muscles lasting until next morning.
Tachycardia (resting heart rate of 120); palpitations; PVCs; exacerbation of POTS; severe, intolerable body aches; full-body trembling; severe fatigue; low-grade fever (99.9 F); mild headache; loss of appetite; symptoms lasted about 20 hours, with fatigue and exacerbation of POTS lasting one additional day
Moderate to severe chest pain beginning within 24 hours of vaccine and lasting for approximately 10 days. Pain increased during strenuous activity and resulted in breathlessness and difficulty breathing due to pain. These symptoms were in addition to fever and chills lasting two days, excessive sweating for two days, and approximately 10 days of joint and muscle pain. Contacted a medical professional who advised the symptoms were similar to that of myocarditis and recommended I monitor the symptoms and self treat with ibuprofen and to seek emergency care if they worsened significantly. Symptoms resolved within 2 weeks with regular ibuprofen use.
Diffuse muscle pain and fatigue over a 4 week period which led to an ER visit on 4/21/21.  Final diagnosis was nontraumatic rhabdomyolysis and patient needed to be treated with IV fluids
09:00 felt like heart was pounding B/P elevated, Pulse normal, resp normal. BENADRYL 25 mg tab 1 given @ 0900 Temp warm repeat dose given @ 09:20 tongue swelling felt throat constricting.
Within an hour my back started hurting, when I got home from work my legs were aching like they needed to be stretched or massaged, the next morning I was sore all over, went to work very tired- no amount of coffee helped, back hurting, legs hurting, bone tired. Left work at 4pm and went right home to bed with 99.8 fever, sweats, pain like the flu. Woke up this morning and my legs don't hurt, no fever-back still hurts and still not feeling quite right- but so much better.
pt recv vax 16JUL93 & same day devel a fever over 102;
This spontaneous report was received from a healthcare worker and refers to multiple unspecified patients of unknown age and gender. The patients' pertinent medical history and concomitant medication were not reported. On 02-NOV-2016 or 03-NOV-2016, the patients were vaccinated with a dose of improperly stored ROTATEQ, route of administration defaulted to oral (dose, frequency, lot# and expiration date were not reported). There was no adverse effect reported. The call was made due to digital data logger. The dose of the administered vaccine was exposed to temperature of 9.5 degrees Celsius for 28 hours. The vaccine was exposed to previous temperature excursion. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
headaches, burning in chest, coughing, increased mucus production, covid test came back negative
Maculopapular rash on lt arm @ the site of inject; 21AUG mom says rash @ inject site cleared p/2wks; fully recovered;
This spontaneous report as received from a consumer via a social webpage, refers to several 'young' patients of unknown age and gender. No medical history or concurrent conditions of the patients were reported. On an unknown date, the patients were vaccinated with GARDASIL for an unknown indication. The reporter stated having 'read stories of these young patients who had been injured by GARDASIL' (injury and adverse event). The outcome of the events was not known. Causality was considered to be related since the reporter stated, 'patients were injured by GARDASIL'. This is one of the two reports from the same source (linked to MARRS number 1607FRA011670). Additional information has been requested
Immediate local reaction AEB swelling to approx 2 inches in diameter.  No redness, itching, rash was evident.  Site observed x 30minutes and ice applied.  Swelling reduced and almost resolved with above interventions.
severe chills 5 hrs p/vax; recvd vax early Oct; intermittent cheeks flushing w/cold extremities & profound weakness & fatigue; cont w/fatigue as of 1NOV93; has seen cardiologist & internist; All blood studies nl but still profound fatigue;
1 1/2 inch induration.  Red, warm, raised, hard and tender.
Patient is fully vaccinated. COVID + on 11/18/2021. 84-year-old gentleman with significant past medical history for diabetes mellitus type 2/hypertension/COPD, who presented due to complaint of shortness of breath.  He has been vaccinated with Moderna back in March 3rd and April 2nd, started having with generalized weakness/fatigue/shortness of breath.  On presentation to the ER, he was noted to have a pulse ox of 70%. Admitting dx:  pneumonia due to COVID.  acute hypoxic respiratory failure.  Treatment:  decadron, remdesivir, ceftriaxone, azithromycin, BiPAP 100% O2.  CXR: bilateral diffuse airspace opacities. D-dimer 539. NSTEMI elevated troponin.AKI.  Heparin drip.  Patient expired.
pt fainted about 3min p/vax;pt then became red in face, arms stiffened for 2-3 sec, became pale around lips-regained consciousness-whole episode lasted less than 1min;BP 68/40-100/60-100/70;
Pt received injections of Lymerix in September and October, 1999 and  for 2 weeks after 2nd shot, he could not lift his arm. He also experienced constant pain and tightness in his right shoulder and all his joints were sore "to some extent". The most recent information received on 2/17/2000, indicates he symptoms are ongoing. Additional information has been request.
2JUN92 pt recvd Engerix-B & 12 hrs p/administartion devel face swelling, tirednedd & h/a; no treatment given;
third dose on JAN2022; first dose on SEP2020, second on NOV202; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 15th September 2020).   On 14th January 2022, the patient received the 3rd dose of Shingrix. On 14th November 2021, the patient received the 2nd dose of Shingrix. On 14th November 2021, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 14th January 2022, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too long were unknown.  Additional details were provided as follows: The reporter stated that a patient received first dose of Shingrix series and then did not return within recommended timeframe for second dose, so the next dose was not administered until 14th November 2021, which led to lengthening of vaccination schedule. The patient's physician ordered a third dose to be administered, which was given on 14th January 2022, which led to extra dose administered. The reporter did not have the lot number and expiration date information for the doses. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022015427:Case duplicate -Deleted
Severe myalgias, headache, neck pain and stiffness, chills, tactile fever, large rash at injection site (persistent on day 4).
6/15/05 linear rash L arm started as red bumps, from finger to scapula. Did not bother child slowly developed and slowly resolved over 2-3 wks, Not taken to doctor. 10/5/05 rash started as "spider (looking) bite  L forearm, next day another developed which looked different - seven "clusters" of vesicular eruptions on erythematous base. Painful X 1 day. (runny nose, unsure if related ) looked like same rash he had in June. Differential diagnosis - dermatitis. herpetiformis - however dermatoma in distribution looks like varicella zoster - but not painful.
This spontaneous report as received from a medical assistant refers to a 12 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 02-OCT-2018, the patient was vaccinated with improperly stored dose of VAQTA ped 0.5 ml vial (dose, frequency and route were not reported) (lot # R009953, expiry date: 12-JUN-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) for 3.5 hours from 06-SEP-2018. Previous excursion was 50.37 °F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868:Original Case : 1809USA002868; US-009507513-1902USA009324:Original Case : 1902USA009323; US-009507513-1902USA009325:Original Case : 1902USA009323; US-009507513-1902USA009326:Original Case : 1902USA009323.
Extreme fatigue,  debilitating motion sickness dizziness cannot walk with out aid to stay upright
Wednesday 4/8 In addition to the expected sore arm, I experienced unusual tightness in my lungs while exercising and had trouble with deep breathing, but those symptoms lessened within 24 hours. Thursday 4/8 sore arm worsened. Took Zyrtec, an allergy medicine. Tightness in chest was less than Wed but still present. Friday 4/9 Terrible stomach pain, diarrhea, and extreme pain in my gall bladder area. Nearly went to ER but nurseline discouraged in absence of a headache, as well.  Acute pain gradually resolved with Benadryl over next few days. Anaphylactic reaction was acute but subsided after a week. However, residual pain in left side of chest , around heart area, intermittently since July 1 when treated with powerful anti-inflammatories.  Waiting for chest scan, which my doctor prescribed. I do not know at this point whether I had heart inflammation or not. Will know soon hopefully.
I work from home and as I was typing I reached for a pen and my shoulder locked up. Began to have muscle aches, joint popping, decreased range of motion, and weakness. Began receiving chiropractic care which relieved symptoms but they return. Having significant issues with weakness and mobility. When I am able to go to the chiropractor the relief lasts 2.5 days. I take TYLENOL and ADVIL for the pain which help make it tolerable. I am in the process of following up with PCP and try to get into PT.
Developed generalized pruritic uricaritc rash; Developed generalized pruritic uricaritc rash; This is a spontaneous report from a contactable consumer (patient). A male patient (Age: 80; Unit: unknown) of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE  , solution for injection), dose 2 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 2, SINGLE; dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced developed generalized pruritic uricaritc rash on an unspecified date. The patient received two doses of vaccine. Developed generalized pruritic uricaritc rash and dermatologist put him on prednisone- relived the itching temporality. Once off prednisone the rash has returned. The patient has another dermatologist appointment today. The patient wanted to know if this side effects has been reported. Therapeutic measures were taken because of developed generalized pruritic uricaritc rash with prednisone. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Cold sweats, chills, possible fever started 11-12 hours after the vaccine was given. Patient also with body aches. The patient developed headache and a swollen, hot, sore injection site in addition to the other symptoms. There was a large red circle around the vaccine site, which persisted for six days. The patient was unable to use the arm in sports for two weeks.
DVT and probable pulmonary embolus based on hypoxia Patient is physician who cares for patients in NH and ALF where there is documented COVID First dose COVID vaccine 12/20/20, second dose 1/10/20 Some shortness of breath developed about 1/10, not severe 1/30 Leg pain, fever to 101.6  abrupt onset  extreme fatigue,  ER eval 1.31 negative eval including neg rapid and PCR COVID tests Persistent sx led to repeat ER eval including LE dopper confirming occlusive femoral vein thromboxis; no hypoxia at rest but desat to 85% on exertion  (climbing one flight of steps) Started anticoagulants 2/4/21 on home treatment; not working since 1/30/21
Redness and severe swelling at the injection site, beginning the day of the injection, and worsening over the next few days. It looked like the skin was going to split because it was so swollen. It took about a week to subside. Treated at home.